A Real World Case Study: Presented by Dr Sarah Lawless
Learn more
HomeArticles
Latest Articles
.png)
A Real World Case Study: Presented by Christine Skeet
Learn more
Gaucher Mechanism of Disease
Learn more
Fabrazyme® (agalsidase beta) evidence
Explore the results and evidence supporting Fabrazyme® and how it was studied through several clinical trials.
Learn more
Fabrazyme® (agalsidase beta) safety profile
Find out more about the safety and tolerability profile for Fabrazyme®.
Learn more
Nexviadyme®▼ (avalglucosidase alfa) safety profile
Find out more about the safety and tolerability profile for Nexviadyme®.
Learn more
Nexviadyme®▼ (avalglucosidase alfa) evidence
Explore the results and evidence supporting Nexviadyme® and how it was studied through several clinical trials.
Learn more
Adopting big data & artificial intelligence to advance diagnosis for rare diseases
Sanofi is working to harness this modern technology to strengthen understanding and diagnostic outcomes for those living with a rare disease.
Learn more
Welcome to Sanofi Campus UK
A hub for healthcare professionals to discover and find information on our medicines and therapies
Learn more
MAT-XU-2305061 (v2.0) Date of preparation: February 2024